ResearcherHenry Ford HealthNo recent work listed

Kenneth N. Barton

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5514-834X; OpenAlex author ID A5010493143. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper

Papers 1

Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Co-author DOI 10.1016/j.omto.2020.11.006 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Munther Ajlouni · 1 shared paper, 2021 · strength 0.12
- Paper Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastati… DOI 10.1016/j.omto.2020.11.006 ↗
David Kwon · 1 shared paper, 2021 · strength 0.12
- Paper Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastati… DOI 10.1016/j.omto.2020.11.006 ↗
Gazala Naaz Khan · 1 shared paper, 2021 · strength 0.12
- Paper Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastati… DOI 10.1016/j.omto.2020.11.006 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.